3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil

14 September 2005. Related: Conference reports, Conference index, IAS 3rd Rio de Janeiro 2005.

This issue of HTB includes reports from this biannual meeting that this year attracted close to 5000 registered delegates.

As with many conferences now, many sessions can be viewed on the internet and provide an excellent opportunity for people who unable to attend the meeting.

Daily conference coverage including webcasts and transcripts of plenary sessions, select press conferences and other sessions, and the opening and closing ceremonies, has been archived and is available for viewing on:
http://www.kaisernetwork.org/rio2005
with links to this site from the IAS conference website:
http://www.ias-2005.org

Abstracts from the meeting are also available to search online although finding them is difficult until AEGiS have completed their archive. Some links from the online programme will access the powerpoint slide used for oral presentations but not the abstracts. The IAS main website also hasn’t added this years meeting to website. Abstracts can be accessed free online in a number of ways:

1. Via the conference schedule planner: http://www.ias-2005.org/planner/
   Links via the ‘programme at a glance’ planner to each section of the programme, include online links to most of the individual abstracts and some of the powerpoint presentations used for the oral sessions.
2. Via the IAS online abstract archieve: http://www.iasociety.org/AbstractSearch.aspx
3. Using AEGiS conference database: http://www.aegis.org/conferences/iashivpt/2005

By far the easiest way will be to use the AEGiS online conference database, and although the full programme had not been archived by the time we went to press, it is expected to be available shortly. Careful proofing undertaken by AEGiS often means that many abstracts are more accurate on this excellent non commercial website.

Reports from the conference

• Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy
• Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS
• New drugs in pregnancy: atazanavir; T20
• Lopinavir/r use in children less than two years old – promising results despite low plasma levels
• Favourable outcomes in children treated with HAART in the MSF programmes
• Encouraging results with cut up generic fixed dose combination tablets in Uganda
• Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire
• Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results
• T20 (enfuvirtide) studies presented at Rio
• Strategies for salvage therapy
• Antiviral activity of foscarnet in salvage patients
• Novel strategies with existing drugs
• Antiretroviral activity of new and novel agents
• Overview of pharmacology studies
• Incidence of TB infection despite HAART and treatment in coinfected patients
• Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients
• Does WHO clinical stage reliably predict who should receive ARV treatment?
• Continuous vs intermittent treatment with triple nuke combination of AZT/3TC/tenofovir in Africa: early results from DART study